IRIS
FRANCHINA, Tindara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.263
NA - Nord America 2.231
AS - Asia 362
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
AF - Africa 1
SA - Sud America 1
Totale 4.866
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.225
SE - Svezia 587
IE - Irlanda 584
CN - Cina 300
PL - Polonia 277
IT - Italia 246
FR - Francia 171
UA - Ucraina 107
DE - Germania 82
FI - Finlandia 72
GB - Regno Unito 52
AT - Austria 34
BE - Belgio 33
IN - India 32
VN - Vietnam 24
RU - Federazione Russa 8
CA - Canada 6
EU - Europa 6
HR - Croazia 3
CH - Svizzera 2
IR - Iran 2
SG - Singapore 2
AU - Australia 1
CL - Cile 1
ES - Italia 1
HU - Ungheria 1
IL - Israele 1
JP - Giappone 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
RO - Romania 1
RS - Serbia 1
ZA - Sudafrica 1
Totale 4.866
Salva come PNG Salva come JPEG
Città #
Dublin 583
Chandler 489
Nyköping 294
Warsaw 274
Jacksonville 240
Beijing 132
Ashburn 121
New York 105
Messina 102
Ann Arbor 97
Dearborn 93
Princeton 93
Medford 82
Cambridge 74
Des Moines 69
Boardman 39
Woodbridge 35
Vienna 34
Brussels 33
Dong Ket 24
Pune 23
San Mateo 23
Wilmington 23
Jinan 22
Shenyang 20
Lancaster 17
Nanjing 16
Fort Washington 14
Grammichele 14
Hebei 12
Taizhou 10
Tianjin 10
Houston 9
Paternò 9
Zhengzhou 9
Hangzhou 8
Leawood 8
Hyderabad 7
Jiaxing 7
Bremen 6
Guangzhou 6
Helsinki 6
Monmouth Junction 6
Ningbo 6
Seattle 6
Auburn Hills 5
Augusta 5
Lanzhou 5
Nanchang 5
Changsha 4
Haikou 4
Taiyuan 4
Brockport 3
Catania 3
Los Angeles 3
Norwalk 3
Novi 3
Ottawa 3
Radomsko 3
Redwood City 3
Rome 3
Scandicci 3
Anagni 2
Ardabil 2
Bordeaux 2
Clearwater 2
Fairfield 2
Falls Church 2
Gravina di Catania 2
Hefei 2
Kemerovo 2
Kunming 2
Linguaglossa 2
Mountain View 2
Novokuznetsk 2
Paris 2
Rüsselsheim 2
Singapore 2
Tappahannock 2
Zurich 2
Achim 1
Acireale 1
Belgrade 1
Budapest 1
Cagliari 1
Centuripe 1
Chengdu 1
Ciampino 1
Cosenza 1
Cupertino 1
Dunedin 1
Edgware 1
Edinburgh 1
Fuzhou 1
Giugliano In Campania 1
Hendon 1
Huzhou 1
Iasi 1
Johannesburg 1
Kumamoto 1
Totale 3.428
Salva come PNG Salva come JPEG
Nome #
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 116
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 101
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 91
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 89
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 89
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 86
NSCLC and HER2: between lights and shadows 82
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 79
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 77
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 75
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 74
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 74
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 73
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 73
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 73
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 73
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 71
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 70
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 70
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 69
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 68
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 68
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 67
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 66
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 65
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 65
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 64
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 64
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 64
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 63
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 61
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 61
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 60
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 60
Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days) 59
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 58
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 58
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 58
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 57
Embolia polmonare 57
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 57
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 56
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 54
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 54
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 53
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 53
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 53
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 52
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 52
null 52
Neoplasie della Testa e del Collo nell'anziano 51
Neoplasie della testa collo nell’ anziano 51
Impact of single-nucleotide polymorphisms in genes coding for folate pathway enzymes on efficacy/toxicity of gemcitabine and pemetrexed based therapy in advanced non small cell lung cancer (NSCLC): new prospectives for old markers. 51
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. 51
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 51
Turbe della nutrizione: anoressia e cachessia. 50
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 50
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 48
Challenges and promises of physical exercise in advances lung cancer patients 48
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 47
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 46
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 46
“Lunga stazionarietà di malattia e clinical benefit con erlotinib in un paziente anziano, forte fumatore, affetto da carcinoma squamoso del polmone”. 45
Emerging targeted therapies for castration-resistant prostate cancer 45
Listening understanding and acting (lung): Focus on communicational issue in thoracic oncology 45
Molecular and clinical analysis of predictive biomarkers to anti-EGFR inhibitors in metastatic colorectal cancer (mCRC): Interaction among early tumor shrinkage, skin toxicities, and RAS status. 43
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 43
POLIMORPHISM OF METHYLENE-TETRAHYDROFOLATE REDUCTASE AND RISK OF LUNG AND COLON-RECTAL CANCER: A CASE CONTROL STUDY 42
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 42
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 41
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 41
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 41
null 40
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. 39
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 39
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database 38
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 37
Invecchiamento e cancro. 36
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 33
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 30
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 28
Use of nivolumab in elderly patients with advanced Non-Squamous NSCLC: results from the Italian Expanded Access Program (EAP) 27
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings 27
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 23
FGFR a promising druggable target in cancer: Molecular biology and new drugs 23
null 22
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 20
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 19
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 17
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 17
Rare histotypes of epithelial biliary tract tumors: A literature review 17
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 15
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 14
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 13
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 11
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 9
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 9
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 6
Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper 5
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database 3
Totale 5.019
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.579
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.579
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201953 0 0 0 0 0 0 0 0 0 0 2 51
2019/2020680 93 24 16 17 8 108 74 82 28 82 100 48
2020/2021853 63 34 131 86 100 70 63 51 40 95 71 49
2021/2022668 6 71 23 19 28 7 29 27 5 163 90 200
2022/20231.841 128 179 74 157 136 184 49 129 724 9 49 23
2023/2024451 25 80 32 29 23 175 60 4 2 21 0 0
Totale 5.022